An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Sponsor
Dompé Farmaceutici S.p.A
Study ID
NCT07503886
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Dry Eye Disease (DED)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DFL24498 — DRUG
    One drop of reconstituted DFL24498 will be instilled topically in each eyes 4 times a day (QID) for 12 weeks.
  • Vehicle — OTHER
    One drop of reconstituted Vehicle will be instilled topically in each eyes QID for 12 weeks.

Study Details

This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease. Approximately 417 participants aged 18 years or older who meet all eligibility criteria will be enrolled at study sites in the US. The study duration will be up to 16 weeks and will consist of three periods.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
Jan 24, 2027
Completion
Feb 7, 2027

Study Design

Enrollment
417 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: DFL24498
    Participants will receive DFL24498 opthalmic solution administered topically in both eyes.
  • Placebo Comparator: Vehicle
    Participants will receive vehicle opthalmic solution administered topically in both eyes.

Primary Outcome Measure

Change from baseline in corneal fluorescein staining (CFS) assessed by National Eye Institute (NEI) scale (0 to 15) in the Study Eye [ Time Frame: Baseline to Week 12 ]

Central Contacts

  • Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
    +39 02 583 831

Related Studies